Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M1 positive allosteric modulator VU0467319 for Alzheimer's disease: a single ascending-dose study in healthy participants.
Saved in:
| Title: | Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M |
|---|---|
| Authors: | Conley AC; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave South, Nashville, TN, 37212, USA., Key AP; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave South, Nashville, TN, 37212, USA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA., Blackford JU; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave South, Nashville, TN, 37212, USA.; Munroe-Meyer Institute, University of Nebraska Medical Center, Omaha, NE, USA., Russell JK; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave South, Nashville, TN, 37212, USA.; Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, CA, USA., Albert KM; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave South, Nashville, TN, 37212, USA., Gong X; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave South, Nashville, TN, 37212, USA., Bubser M; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.; Department of Pharmacology, Vanderbilt University, Nashville, TN, USA., Rook JM; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.; Department of Pharmacology, Vanderbilt University, Nashville, TN, USA., Conn PJ; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.; Department of Pharmacology, Vanderbilt University, Nashville, TN, USA., Lindsley CW; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.; Department of Pharmacology, Vanderbilt University, Nashville, TN, USA., Jones CK; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA.; Department of Pharmacology, Vanderbilt University, Nashville, TN, USA., Newhouse PA; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave South, Nashville, TN, 37212, USA. paul.newhouse@vanderbilt.edu. |
| Source: | Alzheimer's research & therapy [Alzheimers Res Ther] 2025 Jul 01; Vol. 17 (1), pp. 144. Date of Electronic Publication: 2025 Jul 01. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial |
| Journal Info: | Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101511643 Publication Model: Electronic Cited Medium: Internet ISSN: 1758-9193 (Electronic) NLM ISO Abbreviation: Alzheimers Res Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1758-9193 |
|---|---|
| DOI: | 10.1186/s13195-025-01798-4 |
